Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on May 15, 2018. The filing serves to announce the company's financial results for the quarter ended March 31, 2018, which are detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. It solely references the issuance of the press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Harrow, Inc.") and the actual registrant ("Imprimis Pharmaceuticals, Inc.").
- Locate and review Exhibit 99.1 (the Press Release) to obtain actual financial figures for the quarter ended March 31, 2018.
- Confirm whether the press release contains updated guidance or specific risk factors not summarized in this 8-K.